Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients

BACKGROUND: GSK233705 is an inhaled, long-acting muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease (COPD). This study was performed to see if the addition of GSK233705 to salmeterol would provide greater bronchodilation than salmeterol or tiotropium alon...

Descripción completa

Detalles Bibliográficos
Autores principales: Beier, Jutta, van Noord, Jan, Deans, Amanda, Brooks, Jean, Maden, Claire, Baggen, Suus, Mehta, Rashmi, Cahn, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299545/
https://www.ncbi.nlm.nih.gov/pubmed/22419863
http://dx.doi.org/10.2147/COPD.S26100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299545/
https://www.ncbi.nlm.nih.gov/pubmed/22419863
http://dx.doi.org/10.2147/COPD.S26100

Ejemplares similares